Goodwin Procter LLP advised Pear Therapeutics on the deal. Pear Therapeutics announced its definitive business combination agreement with Thimble Point Acquisition Corp. (Nasdaq: THMA), a special purpose...
Pear Therapeutics’ $1.6 Billion Business Combination with Thimble Point Acquisition Corp.
Pear Therapeutics’ $20M Series D Extension
Foley Hoag LLP advised Pear Therapeutics, Inc. on the deal. Pear Therapeutics, Inc., a pioneer of prescription digital therapeutics (PDTs), announced the extension of its Series D...